PART I Our Company We are a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. We are focused on the development and commercialization of innovative product opportunities in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in GI and rare diseases. LINZESS (linaclotide), our commercial product, is the first product approved by the United States Food and Drug Administ...
Q2 FY2026 — expected 2026-09-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001104659-26-020489 | EDGAR | 86K words |
| 2025-03-31 | 2024-12-31 | 0001558370-25-004072 | EDGAR | — |
| 2024-02-16 | 2023-12-31 | 0001558370-24-001275 | EDGAR | — |
| 2023-02-16 | 2022-12-31 | 0001558370-23-001462 | EDGAR | — |
| 2022-02-18 | 2021-12-31 | 0001558370-22-001368 | EDGAR | — |
| 2021-02-17 | 2020-12-31 | 0001558370-21-001136 | EDGAR | — |
| 2020-02-13 | 2019-12-31 | 0001558370-20-000779 | EDGAR | — |
| 2019-02-25 | 2018-12-31 | 0001558370-19-001005 | EDGAR | — |
| 2018-02-22 | 2017-12-31 | 0001558370-18-000927 | EDGAR | — |
| 2017-02-22 | 2016-12-31 | 0001558370-17-000793 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001104659-25-108795 | EDGAR | 28K words |
| 2025-08-11 | 2025-06-30 | 0001558370-25-011050 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001558370-25-007406 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014909 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011590 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001558370-24-007640 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001558370-23-018589 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001558370-23-014242 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001558370-23-008092 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001558370-22-016235 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001558370-22-012191 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001558370-22-007359 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-11 | 0001104659-26-026123 | EDGAR | 1K words |
| 2026-02-25 | 0001104659-26-019405 | EDGAR | — |
| 2026-01-02 | 0001104659-26-000057 | EDGAR | — |
| 2025-12-23 | 0001104659-25-123974 | EDGAR | — |
| 2025-11-26 | 0001104659-25-116217 | EDGAR | — |
| 2025-11-10 | 0001104659-25-108806 | EDGAR | — |
| 2025-10-10 | 0001104659-25-098523 | EDGAR | — |
| 2025-09-03 | 0001104659-25-087008 | EDGAR | — |
| 2025-08-07 | 0001104659-25-074972 | EDGAR | — |
| 2025-07-10 | 0001104659-25-066986 | EDGAR | — |
198 total filings indexed. 166 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001446847 |
| Ticker | IRWD |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.ironwoodpharma.com |
| Listed | 2010-02-03 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report